PMID- 32629751
OWN - NLM
STAT- MEDLINE
DCOM- 20200717
LR  - 20230905
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 27
DP  - 2020 Jul 2
TI  - Brucea javanica oil emulsion injection (BJOEI) as an adjunctive therapy for 
      patients with advanced colorectal carcinoma: A protocol for a systematic review 
      and meta-analysis.
PG  - e21155
LID - 10.1097/MD.0000000000021155 [doi]
LID - e21155
AB  - BACKGROUND: Brucea javanica oil emulsion injection (BJOEI) has been widely 
      applied as a promising adjunctive drug for colorectal carcinoma (CRC). However, 
      the exact effects and safety of BJOEI remains controversial. In this study, we 
      aimed to summarize the efficacy and safety of BJOEI for the treatment of advanced 
      CRC through the meta-analysis, in order to provide scientific reference for the 
      design of future clinical trials. METHODS: Eligible prospective controlled 
      clinical trials were searched from PubMed, Cochrane Library, Google Scholar, 
      Medline, Web of Science (WOS), Excerpt Medica Database (Embase), Chinese 
      BioMedical Database (CBM), China Scientific Journal Database (VIP), China 
      National Knowledge Infrastructure (CNKI) and Wanfang Database. Papers in English 
      or Chinese published from January 2000 to May 2020 will be included without any 
      restrictions. The clinical outcomes including therapeutic effects, quality of 
      life (QoL), immune function and adverse events, were systematically 
      evaluated.Study selection and data extraction will be performed independently by 
      2 reviewers. Review Manager 5.3 and Stata 14.0 were used for data analysis, and a 
      fixed or random-effect model will be used depending upon the heterogeneity 
      observed between trials. Subgroup and meta-regression analysis will be carried 
      out depending on the availability of sufficient data. RESULTS: The results of 
      this systematic review will be published in a peer-reviewed journal. CONCLUSION: 
      Our study will draw an objective conclusion of the effects and safety of BJOEI 
      for advanced CRC, and provide a helpful evidence for clinicians to formulate the 
      best postoperative adjuvant treatment strategy for CRC patients.INPLASY 
      registration number: INPLASY202060014.
FAU - Xu, Chunhong
AU  - Xu C
AD  - Department of Gastroenterology.
FAU - Guo, Xinxin
AU  - Guo X
AD  - Department of Gastroenterology.
FAU - Zhou, Changhui
AU  - Zhou C
AD  - Department of Central Laboratory, Liaocheng People's Hospital, Liaocheng, 
      Shandong Province, China.
FAU - Zhang, Hualing
AU  - Zhang H
AUID- ORCID: 0000-0003-1548-5189
AD  - Department of Gastroenterology.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Emulsions)
SB  - IM
MH  - Brucea/*adverse effects
MH  - Case-Control Studies
MH  - Chemotherapy, Adjuvant/*methods
MH  - China/epidemiology
MH  - Colorectal Neoplasms/*drug therapy/psychology
MH  - Emulsions/*administration & dosage/therapeutic use
MH  - Female
MH  - Humans
MH  - Injections/methods
MH  - Male
MH  - Prospective Studies
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Safety
MH  - Treatment Outcome
MH  - Meta-Analysis as Topic
MH  - Systematic Review as Topic
PMC - PMC7337478
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/07/08 06:00
MHDA- 2020/07/18 06:00
PMCR- 2020/07/02
CRDT- 2020/07/08 06:00
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2020/07/18 06:00 [medline]
PHST- 2020/07/02 00:00 [pmc-release]
AID - 00005792-202007020-00130 [pii]
AID - MD-D-20-05351 [pii]
AID - 10.1097/MD.0000000000021155 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 2;99(27):e21155. doi: 10.1097/MD.0000000000021155.